Clinical Trial Results TV
Merlin TIMI 36 Trial Primary Results by Dr. David Morrow
Dr. David Morrow presents the primary results of the Merlin TIMI 36 trial. Ranolazine
lowered the risk of recurrent ischemia, but it did not prolong life or prevent recurrent
heart attacks. These results confirm medical therapy as a valuable treatment for angina as
suggested by the COURAGE trial. Furthermore, this is the first clinical evidence that the
favorable effects of Ranolazine on the electrical system of the heart seen in animals may
be applied to humans. Keywords: Dr. David Morrow, Ranolazine, Merlin TIMI 36, ischemia,
arrhythmia, angina, COURAGE trial, coronary artery disease, non-ST elevation, medical

[ Download video ]

Video Statistics
5 out of 5

1 Star 2 Star 3 Star 4 Star 5 Star

click a star to vote
This submission has received 2 total votes.

These statistics are updated nightly. The last update ran on
03-22-2018 EST at 1 am.

Additional Files
Filename File Description Action
No additional files available

Comments [ login to comment ]
No comments have been submitted